Results 201 to 210 of about 20,104,039 (259)

Pharmacological Therapy of Chronic Hepatitis C

Chronic hepatitis C is a long-lasting infection caused by hepatitis C virus. The initial treatment for HCV began with the use of interferon-alpha, which was later combined with Ribavirin to improve its effectiveness.
Hsu, Shun Hua
core  

Health System Resilience and Afghan Refugee Health in Pakistan: An Exploratory Study of Challenges and Pathways to Inclusion

The International Journal of Health Planning and Management, EarlyView.
ABSTRACT Pakistan has hosted Afghan refugees for more than four decades, in one of the world's most protracted displacements of people. Afghan refugees receive health services through United Nations High Commissioner for Refugees (UNHCR) and non‐governmental organisation (NGO) supported programmes alongside public sector facilities at every tier.
Zahid Ali Memon, Asma Ummad, Amina Olabi, Natasha Palmer, Sophie Witter   +4 more
wiley   +1 more source

New‐Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank

International Journal of Cancer, EarlyView.
ABSTRACT The prevalence of type 2 diabetes mellitus (T2DM) is rising rapidly in China and is linked to increased cancer risk, but causality remains unclear due to biases. We examined the causal effect of T2DM on cancer risk using bias‐minimizing methods.
Mengying Wang, Owen Tipping, Bowen Liu, Derrick A. Bennett, Baiyong Shen, Siyi Zou, Shulin Zhao, Richard M. Martin, Matthew Sperrin, Andrew G. Renehan   +9 more
wiley   +1 more source

Comparison of Healthcare Utilization Before Diagnosis Between Non‐Advanced and Advanced Lung Cancer Patients: A Study Among 72,851 Cases in Germany

International Journal of Cancer, EarlyView.
ABSTRACT There is no study from Germany on the association between stage of lung cancer (LC) and patient characteristics. We aimed to compare advanced versus non‐advanced LC cases regarding indicators of healthcare utilization. Using claims data covering 20% of the German population, we included LC patients diagnosed between 2013 and 2019.
Josephine Küsel‐Kanbach, Oliver Riedel, Ulrike Haug   +2 more
wiley   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

[Chronic hepatitis C].

Revista de gastroenterologia de Mexico, 2014
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Chronic hepatitis C

Current Treatment Options in Gastroenterology, 2001
Infection with hepatitis C virus (HCV) accounts for 40% of cases of chronic liver disease in the United States and is now the most common indication for liver transplantation. Estimates suggest that 4 million people (1.8%) of the American population are or have been infected with HCV.
Tram T., Tran, Paul, Martin
openaire   +2 more sources

Update on Chronic Hepatitis C

Comprehensive Therapy, 2003
Strategies for the diagnosis and treatment of chronic hepatitis C continue to evolve. Liver biopsy is now used selectively rather than routinely, and the combination peginterferon plus ribavirin is the treatment of choice for the majority of patients.
Aijaz, Ahmed, Emmet B, Keeffe
openaire   +2 more sources

Hepatic Granulomas in Chronic Hepatitis C

Journal of Clinical Gastroenterology, 2001
[No abstract available]
Mert, A, Tabak, F, Ozaras, R, Tahan, V, Senturk, H, Ozbay, G   +5 more
openaire   +2 more sources

The Prevalence of Hepatic Granulomas in Chronic Hepatitis C

Journal of Clinical Gastroenterology, 2004
Hepatic granulomas are not usual findings in chronic hepatitis C. A few studies addressing the frequency of hepatic granulomas in chronic hepatitis C reported it as less than 10%. The presence of it has been suggested to predict a favorable response to interferon treatment.
Mert, A, Celikel, CA, Tozun, N, Senturk, H, Ozaras, R, Tahan, V, Ozbay, G, Avsar, E, Tabak, F, Kanat, M, Uraz, S   +10 more
openaire   +4 more sources